Eli Lilly and Company is a Strong Buy due to strong growth in obesity and diabetes drugs and pipeline innovation. Learn more ...

On Oct. 30, Eli Lilly will announce third-quarter earnings results that could lift the stock, or pressure it further. Here ...

Eli Lilly signed an agreement with Cipla , allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a ...

Eli Lilly is poised to leapfrog Novo Nordisk and become the dominant player in an anti-obesity drug market that could reach ...

Eli Lilly has teamed up with Cipla to market its popular weight-loss drug Mounjaro in India. The medication, which is used ...

While most of what the FDA laid out in a recent draft guidance on the assessment of overall survival in oncology clinical ...

Eli Lilly and Company (NYSE:LLY) is one of the best long term low volatility stocks to buy right now. On October 17, J.P.

Eli Lilly was looking for infrastructure and an uncomplicated permit process for its $6.5M pharmaceutical manufacturing ...

Eli Lilly and Co. is expanding its real estate footprint in Boston’s Seaport district with a new lease for 75,000 square feet ...

Indian drugmaker Cipla signed an agreement with Eli Lilly to sell tirzepatide, the active ingredient in the U.S. company’s weight-loss drug Mounjaro, in India, the companies announced on Thursday.

Under the agreement, Cipla will market the drug under a new brand name, Yurpeak, while Lilly continues to sell it as Mounjaro ...

Eli Lilly has signed a licensing deal with Cipla to market its blockbuster weight-loss drug under the brand name Yurpeak in ...